

Reference list

I. ANTIPSYCHOTICS/NEUROLEPTICS

Typical

Chlorpromazine – Clinical

- Laborit H, Huguenard P, Alluaume R. *Un nouveau stabilisateur végétatif (LE 4560RP)*. Presse Med 1952; 60: 206-208. (page 1)
- Delay J, Deniker P, Harl JM. *Utilisation en thérapeutique psychiatrique d'une phénothiazine d'action centrale élective (4560 RP)*. Ann Med Psychol (Paris) 1952; 110: 112-131. (page 7)

Chlorpromazine – Basic

- Courvoisier S, Fournel J, Ducrot R, Kolsky M, Koetschet P. *Propriétés pharmacodynamiques du chlorhydrate de chloro-3 (diméthylamino-3' propyl)-10 phénothiazine (4.560 R.P.)*. Arch int Pharmacodyn 1953; 92: 305-361. (page 29)
- Courvoisier S. *Pharmacodynamic basis for the use of chlorpromazine in psychiatry*. J Clin Exp Psychopathol 1956; 17: 25-37.

Haloperidol – Clinical

- Brandrup E, Kristjansen P. *A controlled clinical test of a new psycholeptic drug (haloperidol)*. J Ment Sci 1961; 107: 778-782. (page 89)

Haloperidol – Basic

- Janssen PAJ. *The butyrophenone story*. In: Ayd FJ Jr, Blackwell B, editors. Discoveries in biological psychiatry. Philadelphia (PA): Lippincott Williams & Wilkins; 1970. p. 165-179. (page 97)

Dopamine Hypothesis of Schizophrenia

- Seeman P, Lee T. *Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neurons*. Science 1975; 188: 1217-1219.
- Seeman P, Chau-Wong M, Tedesco J, Wong K. *Brain receptors for antipsychotic drugs and dopamine: Direct binding assays*. Proc Natl Acad Sci USA 1975; 72: 4376-4380.
- Seeman P, Lee T, Chau-Wong M, Wong K. *Antipsychotic drug doses and neuroleptic/dopamine receptors*. Nature 1976; 261: 717-719. (page 115)
- Carlsson A. *The current status of the dopamine hypothesis of schizophrenia*. Neuropsychopharmacol 1988; 1: 179-186. (page 119)

Reprinted with all comments and the reply (pages 129-145)

Atypical

Clozapine – Clinical

- Kane J, Honigfeld G, Singer J, Meltzer H. *Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine*. Arch Gen Psychiatry 1988; 45: 789-796. (page 147)
- Hippus H. *The history of clozapine*. Psychopharmacology (Berl) 1989; 99: S3-S5.

Clozapine – Mechanisms of Action

- Meltzer HY. *Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia*. Psychopharmacology (Berl) 1989; 99: S18-S27. (page 157)

II. ANTIDEPRESSANTS

MAO Inhibitors

Iproniazid – Clinical

- Crane GE. *Iproniazid (Marsilid®) phosphate, a therapeutic agent or mental disorders and debilitating disease*. Psychiatric Res Reports 1957; 8: 142-152. (page 169)

- Kline NS. *Clinical experience with iproniazid (Marsilid®)*. J Clin Exp Psychopathol 1958; 19: 27-28.

Iproniazid – Mechanism of Action

- Zeller E.A. *Diamine oxidase*. In: Boyer PD, Lardy H, Myrback K, editors. The enzymes. Vol. 8. 2nd ed. London: Academic Press; 1952. p. 313-335.

Basic/Clinical MAO Inhibitors

- Murphy DL, Garrick NA, Aulakh CS, Cohen RM. *New contributions from basic science to understanding the effects of monoamine oxidase inhibiting antidepressants*. J Clin Psychiatry 1984; 45: 37-43.

Tricyclics/Tetracyclics

Imipramine – Clinical

- Kuhn R. *The treatment of depressive states with G22355 (imipramine hydrochloride)*. Am J Psychiatry 1958; 115: 459-464. (page 183)

Neurotransmitters in depression

- Brodie BB, Olin JS, Kuntzman RG, Shore PA. *Possible interrelationship between release of brain norepinephrine and serotonin by reserpine*. Science 1957; 125: 1293-1294.
- Brodie BB, Shore PA. *A concept for a role of serotonin and norepinephrine as chemical mediators in the brain*. Ann NY Acad Sci 1957; 66: 631-641. (page 191)
- Schildkraut JJ. *The catecholamine hypothesis of affective disorders: A review of supporting evidence*. Am J Psychiatry 1965; 122: 509-522.

Selective Serotonin Reuptake Inhibitors

Serotonin Hypothesis of Depression

- Coppen AJ. *Depressed states and indolealkylamines*. Adv Pharmacol 1968; 6: 283-291.
- Coppen A, Prange AJ Jr., Whybrow PC, Noguera R. *Abnormalities of indoleamines in affective disorders*. Arch Gen Psychiatry 1972; 26: 474-478.
- Coppen A, Wood K. *5-Hydroxytryptamine in the pathogenesis of affective disorders*. Adv Biochem Psychopharmacol 1982; 34: 249-258.
- Lapin IP, Oxenkrug GF. *Intensification of the central serotonergic processes as a possible determinant of the thymoleptic effect*. Lancet 1969; 1: 132-136. (page 205)

- Van Praag HM, Kahn R, Asnis GM, Lemus CZ, Brown SL. *Therapeutic indications for serotonin-potentiating compounds: A hypothesis*. Biol Psychiatry 1987; 22: 205-212.

Zimelidine – Clinical

- Siwers B, Ringberger VA, Tuck JR, Sjöqvist F. *Initial clinical trial based on biochemical methodology of zimelidine (a serotonin uptake inhibitor) in depressed patients*. Clin Pharmacol Ther 1977; 21: 194-200. (page 213)

Fluoxetine – Basic

- Wong DT, Bymaster FP, Horng JS, Molloy BB. *A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine*. J Pharmacol Exp Ther 1975; 193: 804-811. (page 223)

III. ANTIANXIETY AGENTS

Discovery of Benzodiazepines

- Randall LO, Schallek W, Heise GA, Keith EF, Bagdo RE. *The psychosedative properties of methaminodiazepoxide*. J Pharmacol Exp Ther 1960; 129: 163-171. (page 233)
- Sternbach LH, Randall LO, Gustafson SR. In: Gordon M, editor. Psychopharmacological agents. Vol. 1. New York: Academic Press; 1964. p. 137-224.

Chlordiazepoxide – Clinical

- Harris TH. *Methaminodiazepoxide*. JAMA 1960; 172: 1162-1163.

Active Metabolites of Chlordiazepoxide/Benzodiazepine Antagonists

- Christensen JD. *Tolerance development with chlordiazepoxide in relation to the plasma level of the parent compound with its main metabolites in mice*. Acta Pharmacol Toxicol (Copenh) 1973; 33: 262-272. (page 245)
- Hunkeler W, Möhler H, Pieri I, Pole P, Bonetti EP, Cumin R, et al. *Selective antagonists of benzodiazepines*. Nature 1981; 290: 514-516. (page 259)
- Haefely W. *Antagonists of benzodiazepines: Functional aspects*. In: Biggio G, Costa E, editors. Benzodiazepine recognition site ligands: Biochemistry and pharmacology. New York: Raven Press; 1983. p. 73-93.

Benzodiazepine - Mechanisms of Action

- Costa E, Guidotti A, Mao CC, Suria A. *New concepts on the mechanism of action of benzodiazepines*. Life Sci 1975;17: 167-185. (page 265)
- Polc P, Mohler H, Haefely W. The effect of diazepam on spinal cord activities: Possible sites and mechanisms of action. Naunyn Schmiedebergs Arch Pharmacol 1974; 284: 319-337.
- Haefely W, Kulcsar A, Mohler H, Pieri L, Polc P, Schaffner R. *Possible involvement of GABA in the central actions of benzodiazepines*. Adv Biochem Psychopharmacol 1975; 131-151.

IV. MOOD STABILIZING AGENTS

Lithium

- Cade JFJ. *Lithium salts in the treatment of psychotic excitement*. Med J Aust 1949; 36: 349-351. (page 287)
- Schou M, Juel-Nielson N, Strömngren E, Voldby H. *The treatment of manic psychoses by the administration of lithium salts*. J Neurol Neurosurg Psychiat 1954; 17: 250-260. (page 293)
- Baastrup PC, Schou M. *Lithium as a prophylactic agent: Its effect against recurrent depressions and manic-depressive psychosis*. Arch Gen Psychiatry 1967; 16: 162-172. (page 307)

Anticonvulsants as Mood Stabilizers

- Small JG. *Anticonvulsants in affective disorders*. Psychopharmacol Bull 1990; 26: 25-36.
- Post RM, Weiss SR, Chuang DM. *Mechanisms of action of anticonvulsants in affective disorders: Comparisons with lithium*. J Clin Psychopharmacol 1992; 12: 23S-35S.

V. OPIOIDS

N-Allyl-Normorphine – a Narcotic Antagonist

Basic

- Hart ER. *N-allylnorcodeine and N-allyl-normorphine, two antagonists to morphine*. J Pharmacol Exp Ther 1941; 72: 19. (page 321)

- Unna K. *Antagonistic effect of N-allyl-normorphine upon morphine*. J Pharmacol Exp Ther 1943; 79: 27-31.
- Wikler A, Carter RL. *Effects of single doses of N-allylnormorphine on hindlimb reflexes of chronic spinal dogs during cycles of morphine addiction*. J Pharmacol Exp Ther 1953; 109: 92-101.

Clinical

- Echenhoff JE, Elder JD, King BD. *N-allyl-normorphine in the treatment of morphine or demerol narcosis*. Am J Med Sci 1952; 223: 191-197.

Methadone Therapy Maintenance

- Dole VP, Nyswander M. *A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride*. JAMA 1965; 193: 646-650. (page 325)
- Dole VP, Nyswander ME, Kreek MJ. *Narcotic blockade*. Arch Intern Med 1966; 118: 304-309.

Discovery of Opioid Receptors

- Goldstein A, Lowney LI, Pal BK. *Stereospecific and nonspecific interactions of the congener morphine levorphanol in subcellular fractions of mouse brain*. Proc Natl Acad Sci USA 1971; 68: 1742-1747. (page 333)
- Pert CB, Snyder SH. *Opiate receptor: Demonstration in nervous tissue*. Science 1973; 179: 1011-1014. (page 341)
- Simon EJ, Hiller JM, Edelman I. *Stereospecific binding of the potent narcotic analgesic (3H) Etorphine to rat-brain homogenate*. Proc Natl Acad Sci USA 1973; 70: 1947-1949.
- Terenius L. *Stereospecific interaction between narcotic analgesics and a synaptic plasma membrane fraction of rat cerebral cortex*. Acta Pharmacol Toxicol (Copenh) 1973; 32: 317-320.

Discovery of Endogenous Opioid Peptides

- Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR. *Identification of two related pentapeptides from the brain with potent opiate agonist activity*. Nature 1975; 258: 577-579. (page 347)
- Kosterlitz HW, Hughes J. *Some thoughts on the significance of enkephalin, the endogenous ligand*. Life Sci 1975; 17: 91-96.

VI. PSYCHOTOMIMETICS

Mind Altering Drugs

- Lewin L. *Phantastica; narcotic and stimulating drugs, their use and abuse.* London: Routledge K Paul; 1964.

Cannabis - Hashish, Marijuana

Clinical

- Moreau JJ. *Du hachisch et de l'aliénation mentale. Études psychologiques.* Paris: Fortin, Masson et Cie; 1845.
- Moreau JJ. *Hashish and mental illness* (English translation by G.J. Barnett). Peters H, Nahas GG, editors. New York: Raven Press; 1973.

Basic

- Devane WA, Dysarz FA III, Johnson MR, Melvin LS, Howlett AC. *Determination and characterization of a cannabinoid receptor in rat brain.* Mol Pharmacol 1988; 34: 605-613. (page 353)

Mescaline

- Klüver H. *Mescal: The "divine" plant and its psychological effects.* London: Keagan Paul, Trench, Trubner and Co., 1928.
- Klüver H. *Mescal and mechanisms of hallucinations.* Chicago: The University of Chicago Press; 1966.

LSD-25

Clinical

- Stoll WA. *Lysergsäure-diäthylamid, ein Phantastikum aus der Mutterkorn-gruppe.* Schweiz Arch Neurol Neurochir Psychiat 1947; 60: 279-323.

Basic

- Gaddum JH. *Antagonism between lysergic acid diethylamide and 5-hydroxy-tryptamine.* J Physiol 1953; 121: 15P.
- Hofmann A. *Psychotomimetic drugs: Chemical and pharmacological aspects.* Acta Physiol Pharmacol Neerl 1959; 8: 240-258. (page 365)

Comprehensive and Historical

- Siva Sankar DV. LSD: A total study. Westbury NY: PJD Publications Ltd.; 1975.
- Hofmann A. LSD: Main Sorgenkind. Stuttgart: Klett-Cotta; 1979.
- Hofmann A. LSD: My problem child (English translation, Ott J). New York: McGraw Hill Book Co.; 1980.

Dissociative Anesthetics

Phencyclidine – Clinical

- Greifenstein F, DeVault M, Yoshitake J, Gajewski JE. *A study of 1-arylcyclohexylamine for anesthesia*. Anesth Analg 1958; 37: 283-294.
- Meyer J, Greifenstein F, DeVault M. *A new drug causing symptoms of sensory deprivation*. J Nerv Ment Dis 1959; 129: 54-61.
- Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R. *Study of a new schizophrenomimetic drug - Sernyl*. AMA Arch Neurol Psychiat 1959; 81: 363-369. (page 387)

Phencyclidine – Basic and Historical

- Lodge D, Anis NA, Berry SC, Burton NR. Arylcylcohexylamines selectively reduce excitation of mammalian neurons by aspartate-like amino acids. In: Kamenka J-M, Domino EF, Geneste P, editors. Phencyclidine and related arylcyclohexylamines: present and future applications. Ann Arbor, MI: NPP Books; 1983. p. 595-616.

Ketamine – Clinical

- Domino EF, Chodoff P, Corssen G. *Pharmacologic effects of CI-581, a new dissociative anesthetic, in man*. Clin Pharmacol Ther 1965; 6: 279-291. (page 397)

VII. ROLE OF BEHAVIORAL PHARMACOLOGY AND CONCEPT OF REINFORCEMENT

Conditioning and Learning

- Wikler A. *Dynamics of drug dependence: Implications of a conditioning theory for research and treatment*. Arch Gen Psychiatry 1973; 28: 611-616. (page 413)

Self-Stimulation Behaviour

- Olds J, Milner P. *Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain.* J Comp Physiol Psychol 1954; 47: 419-427.

Drug Self-Administration

- Deneau G, Yanagita T, Seevers MH. *Self-administration of psychoactive substances by the monkey: A measure of psychological dependence.* Psychopharmacology (Berl) 1969; 16: 30-48. (page 421)